On March 14, AstraZeneca plans to buy Amolyt Pharma, a biotech firm specializing in rare endocrine disorders, enhancing its Alexion unit with the phase III drug, eneboparatide, for hypoparathyroidism treatment.
Sosei Heptares reclaims complete control over HTL0027477 from GSK, a pioneering oral GPR35 activator set for clinical trials in treating inflammatory bowel conditions.
ACELYRIN, INC. has revealed encouraging initial data from its Phase 1/2 studies for Lonigutamab. This first-of-its-kind, injectable treatment targeting IGF-1R has shown promising therapeutic effects in patients suffering from Thyroid Eye Disease.
On March 20th, Idorsia, a Swiss pharma, announced FDA approval for their drug TRYVIO™ (aprocitentan) to be used alongside other antihypertensives for treating uncontrolled hypertension in adults.
Pharmacovigilance is the science and practice of monitoring the safety and adverse effects of medications that are prescribed, sold, or otherwise in use.